Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use.

Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID business. During a four-hour investor event last week, Pfizer pushed its initative ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

The truth is that cancer has touched or will touch most people’s lives in some way; one in three people in the U.S. are expected to receive a cancer diagnosis in their lifetime.[1] And alarmingly, ...

Pfizer is expected to experience growth in cancer treatments due to the rising global incidence of cancer, particularly aggressive forms, in young adults. Recent acquisitions, including Seagen and ...

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue. The pharmaceutical giant said Monday it will pay $229 ...

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue. The pharmaceutical giant said Monday it will pay $229 ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematology (ASH) Annual ...

Pfizer will spend $43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay $229 in cash for each Seagen share. Bothell, ...

Pfizer announced this week it plans to acquire Seagen, a biotechnology company focused on cancer treatments, in a deal valued at $43 billion. New York-based drug giant Pfizer, which has a facility in ...